OPRD1 (Ser363) Polyclonal Antibody

Formalin-fixed and paraffin embedded human neurological glioblastoma labeled with Anti-OPRD1 (Ser363) Polyclonal Antibody, Unconjugated (bs-20197R) at 1:200 followed by conjugation to the secondary antibody and DAB staining.

Formalin-fixed and paraffin embedded human Neurological glioblastoma labeled with Anti-OPRD1 (Ser363) Polyclonal Antibody, Unconjugated (bs-20197R) at 1:200 followed by conjugation to the secondary antibody and DAB staining

$Paraformaldehyde-fixed, paraffin embedded rat brain tissue; Antigen retrieval by boiling in sodium citrate buffer(pH6) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 20min; Antibody incubation with Rabbit Anti-OPRD1 (Ser363) Polyclonal Antibody, Unconjugated (bs-20197R) at 1:500 overnight at 4\u00b0C, followed by a conjugated secondary and DAB staining$

Paraformaldehyde-fixed, paraffin embedded rat brain tissue; Antigen retrieval by boiling in sodium citrate buffer(pH6) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 20min; Antibody incubation with Rabbit Anti-OPRD1 (Ser363) Polyclonal Antibody, Unconjugated (bs-20197R) at 1:500 overnight at 4\u00b0C, followed by a conjugated secondary and DAB staining

$Lane 1: Mouse Cerebrum tissue lysates; Lane 2: Mouse Cerebellum tissue lysates; Lane 3: Rat Cerebrum tissue lysates; Lane 4: Rat Cerebellum tissue lysates probed with Phospho-delta Opioid Receptor (Ser363) Polyclonal Antibody, Unconjugated (bs-20197R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.$

Lane 1: Mouse Cerebrum tissue lysates; Lane 2: Mouse Cerebellum tissue lysates; Lane 3: Rat Cerebrum tissue lysates; Lane 4: Rat Cerebellum tissue lysates probed with Phospho-delta Opioid Receptor (Ser363) Polyclonal Antibody, Unconjugated (bs-20197R) at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.

Applications

WB
ELISA
FCM
IHC-P
IHC-F
IF(IHC-P)
IF(IHC-F)
IF(ICC)
ICC

Reactivity

Human
Mouse
Rat

Predicted Reactivity

Cow
Chicken
Rabbit

Overview
Catalog #	bs-20197R
Product Name	OPRD1 (Ser363) Polyclonal Antibody
Applications	WB, ELISA, FCM, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC
Specificity	This phosphorylation site is homologous in the listed cross reactive species at the specified location.
Reactivity	Human, Mouse, Rat
Predicted Reactivity	Cow, Chicken, Rabbit
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human OPRD1 around the phosphorylation site of TP(p-S)DG
Modification Site	Ser363
Clonality	Polyclonal
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	4985
Swiss Prot	P41143
Subcellular location	Cell membrane
Synonyms	OPRD; Delta-type opioid receptor; D-OR-1; DOR-1; OPRD1
Background	G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine.
Application Dilution
WB	1:300-5000
ELISA	1:500-1000
FCM	1:20-100
IHC-P	1:200-400
IHC-F	1:100-500
IF(IHC-P)	1:50-200
IF(IHC-F)	1:50-200
IF(ICC)	1:50-200
ICC	1:100-500